Menu
Recruiting NCT07187882

Autologous Non-cultured Epidermal Cell Suspension Transplantation in the Treatment of Vitiligo

No phase Interventional Vitiligo

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Autologous Non-cultured Epidermal Cell Suspension transplantation.
Who it may be relevant to
Registry conditions: Vitiligo. Basic parameters: 8 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

To observe the long-term efficacy and safety of autologous non cultured epidermal cell suspension transplantation in the treatment of vitiligo, analyze the correlation between cell density, type, and postoperative efficacy and prognosis, and providing a basis for clinical application.

Detailed description

1\. Patient recruitment Inclusion criteria:

1. Patients diagnosed as vitiligo, according to the "Vitiligo Diagnosis and Treatment Consensus (2021 edition) 2. Segmental and unclassified vitiligo stable for 6 months, Non-segmental vitiligo stable for 1 year and resistant to medication and phototherapy 3. BSA≥5% 4. Sign the informed consent and be willing to undergo surgical treatment 5. 8-65 years old, both genders Exclusion criteria:

1\) Severe visceral or infectious disease not suitable for surgical treatment 2) Tendency toward keloid formation 3) Coagulation defects 4) Unable to complete follow-up on time 2. Non-cultured epidermal cell suspension transplantation procedure

1. Thin split thickness skin grafts of about one-tenth of the recipient area were taken from the donor site(anterolateral thigh)after aseptic precautions. 2. The suspension for non-cultured epidermal cell suspension transplantation was prepared by the cell sorting kit (Primcell, Jiangsu Repatec Life Science Co.,Ltd). 3. The recipient site was cleaned with 75% alcohol and anesthetized by applying topical compound lidocaine cream for 45 to 60 minutes. Then the recipient skin was uniformly dermabraded using an electrical dermabrader set at 10,000 to 20,000 rpm until punctate bleeding points appeared. Dermabrasion was performed 0.5 mm beyond the margin of the recipient area to minimize the perigraft halo of depigmentation. 4. The cell suspension was applied onto the dermabraded recipient area. The recipient site was then fixed firmly with 4 layers of dressing. From the inner to the outer layer, these dressings were: non adherent wound dressing , paraffin-embedded gauze, dry gauze, and elastic bandage. The dressings were removed 10 days after transplantation.

3\. Postoperative Follow-Up All patients returned to the hospital for follow-up examinations at 2 weeks, 1month, 2 months, 3 months, 4 months, 5 months and 6 months after transplantation.

The repigmentation was graded based on the percentage of the area of repigmentation as poor (less than 25%), good (26%-50%), very good (51%-75%), or excellent (more than 75%).

The melanin index (MI) and erythema index (EI) of the recipient sites were measured using a Mexameter MX18 (Courage 1Khazaka Electronic GmbH, Koln, Germany). The relative MI (RMI) and relative EI (REI) were calculated as the ratio of the MI or EI of the recipient sites relative to the symmetrical control skin region.

4\. Laboratory Tests The cell number and vitality of the suspension was determined by an automatic intelligent cell counter. The flow cytometry was used to analyze the cell types.

Interventions

  • Procedure Autologous Non-cultured Epidermal Cell Suspension transplantation
    1. Thin split thickness skin grafts were taken from the donor site (anterolateral thigh) after application of topical anaesthesia under complete aseptic precautions. 2. The cell suspension was prepared by the cell sorting kit (Primcell, Jiangsu Repatec Life Science Co.,Ltd). 3. Then the recipient skin was uniformly dermabraded using an electrical dermabrader set at 10,000 to 20,000 rpm until punctate bleeding points appeared. 4. The cell suspension was applied onto the dermabraded recipient area

Primary outcome measures

  • Repigmentation rate [Time frame: 2 weeks, 1month, 2 months, 3 months, 4 months, 5 months and 6 months after transplantation]
Secondary outcome measures (2)
  • Relative Melanin Index [Time frame: 2 weeks, 1month, 2 months, 3 months, 4 months, 5 months and 6 months after transplantation]
  • Relative erythema index [Time frame: 2 weeks, 1month, 2 months, 3 months, 4 months, 5 months and 6 months after transplantation]

Eligibility criteria

Inclusion criteria

  • Patients diagnosed as vitiligo, according to the "Vitiligo Diagnosis and Treatment Consensus (2021 edition)
  • Segmental and unclassified vitiligo stable for 6 months, Non-segmental vitiligo stable for 1 year and resistant to medication and phototherapy
  • BSA≥5%
  • Sign the informed consent and be willing to undergo surgical treatment
  • 8-65 years old, both genders

Exclusion criteria

  • Severe visceral or infectious disease not suitable for surgical treatment
  • Tendency toward keloid formation
  • Coagulation defects
  • Unable to complete follow-up on time

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • Peking University People's Hospital — Beijing

Identifiers

NCT: NCT07187882 · RDL2023-04

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗